Biocon Biologics gets USFDA nod for diabetes medication

Biocon Biologics has secured USFDA approval for Kirsty. Kirsty is an interchangeable biosimilar to NovoLog, used for diabetes treatment. It is a rapid-acting insulin analog. The medication will be available in prefilled pens and vials. This approval expands Biocon's insulin portfolio. Kirsty has been available in Europe and Canada since 2022. The US market for Insulin Aspart is significant.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/t5qvzBc
via IFTTT